Asian Journal of Research and Reports in Ophthalmology

A Rare Report of Dominant Optic Atrophy/Kjer’s Disease

Sarra Lakrimi *

Department of Ophthalmology, University Hospital Center Mohammed VIth Oujda, Morocco.

Malik Alkteish

Department of Ophthalmology, University Hospital Center Mohammed VIth Oujda, Morocco.

Manal Chafik

Department of Ophthalmology, University Hospital Center Mohammed VIth Oujda, Morocco.

Nooh Abutabeekh

Department of Ophthalmology, University Hospital Center Mohammed VIth Oujda, Morocco.

Siham Chariba

Department of Ophthalmology, University Hospital Center Mohammed VIth Oujda, Morocco.

Asmae Maadane

Department of Ophthalmology, University Hospital Center Mohammed VIth Oujda, Morocco.

Rachid Sekhsoukh

Department of Ophthalmology, University Hospital Center Mohammed VIth Oujda, Morocco.

*Author to whom correspondence should be addressed.

---

Abstract

Dominant optic atrophy (DOA) orKjer's disease, caused by mutations in the OPA1 gene, is an autosomal dominant inherited pathology due to degeneration of retinal ganglion cells leading to loss of optic nerve axons. It manifests itself in atrophy of the optic nerve head, which, together with the decrease in visual acuity, alteration of the visual field and dyschromatopsia, is one of the essential elements of the diagnosis. Its molecular diagnosis (OPA1 genes in 60% of cases) allows nowadays an informed genetic counselling in the majority of cases. This disease is associated with the susceptibility of retinal ganglion cells to mitochondrial deficits, particularly affecting the respiratory chain, mitochondrial network dynamics, mitochondrial control of apoptosis, and inner membrane patterning. These molecular abnormalities underlie pathophysiological mechanisms, knowledge of which opens potential therapeutic opportunities (neuroprotectors, antioxidants, gene therapy).

Case Presentation: The 22-year-old patient has experienced progressive bilateral visual acuity loss since childhood. Ophthalmologic examination showed bilateral temporal papilledema atrophy. The diagnosis of Dominant optic atrophy was confirmed through genetic testing, which detected the OPA1 gene mutation in the patient, as well as her father and grandmother.

Conclusion: Despite ongoing research efforts to improve the characterization of the disease, Dominant optic atrophy remains a rare condition that is often not diagnosed promptly. The development of therapies for the disease is dependent on gaining a better understanding of it.

Keywords: Dominant optic atrophy, autosomal, retinal ganglion cells, dyschromatopsia, visual field defect, OPA1 gene

---

---

---

References

Kjer P. Infantile optic atrophy with dominant mode of inheritance: A clinical and genetic study of 19 danish families. Acta Ophthalmol Suppl. 1959;164(Supp 54):1–147.

Taban M, Cohen BH, David Rothner A, Traboulsi EI. Association of optic nerve hypoplasia with mitochondrial cytopathies. J Child Neurol. 2006;21(11):956–960.

Delettre C, Lenaers G, Pelloquin L, Belenguer P, Hamel CP. OPA1 (Kjer type) dominant optic atrophy: A novel mitochondrial disease. Mol Genet Metab. 2002;75(2):97–107.

Amati-Bonneau P, Milea D, Bonneau D, Chevrollier A, Ferre M, Guillet V, Gueguen N, Loiseau D, de Crescenzo MA, Verny C, et al. OPA1-associated disorders: Phenotypes and pathophysiology. Int J Biochem Cell Biol. 2009;41(10):1855–1865.

Thiselton DL, Alexander C, Taanman JW, Brooks S, Rosenberg T, Eiberg H, Andreasson S, Van Regemorter N, Munier FL, Moore AT, et al. A comprehensive survey of mutations in the OPA1 gene in patients with autosomal dominant optic atrophy. Invest Ophthalmol Vis Sci. 2002;43(6):1715–1724.

Yu-Wai-Man P, Griffiths PG, Burke A, Sellar PW, Clarke MP, Gnanaraj L, AhKine D, Hudson G, Czermin B, Taylor RW, et al. The prevalence and natural history of dominant optic atrophy due to OPA1 mutations. Ophthalmology. 2010;117(8): 1531–1546.

Newman NJ. Hereditary Optic Neuropathies: from the mitochondria to the optic nerve. Am J Ophthal. 2005;140(3): 517-523.

Kline LB, Glaser JS. Dominant optic atrophy: The clinical profile. Arch Ophthalmol. 1979;97(9):245-251.

Delettre C, Lenaers G, et al. OPA1 (Kjer type) dominant optic atrophy: A novel mitochondrial disease. Mol Genet Metab. 2002;75(2):97-107.

Chun BY, Rizzo JF 3rd. Dominant optic atrophy and leber's hereditary optic neuropathy: Update on clinical features and current therapeutic approaches. Semin Pediatr Neurol. 2017;24(2):129-134.

Yu-Wai-Man P, Votruba M, Moore AT, Chinnery PF. Treatment strategies for inherited optic neuropathies: past, present and future. Eye (Lond). 2014;28(5):521-37.

Skidd PM, Lessell S, Cestari DM. Autosomal dominant hereditary optic neuropathy (ADOA): A review of the genetics and clinical manifestations of ADOA and ADOA+. Semin Ophthalmol. 2013;28(5-6):422-6.

Carelli V, La Morgia C, Sadun AA. Mitochondrial dysfunction in optic neuropathies: Animal models and therapeutic options. CurrOpin Neurol. 2013;26(1):52-58.

Ham M, Han J, Osann K, Smith M, Kimonis V. Meta-analysis of genotype-phenotype analysis of OPA1 mutations in autosomal dominant optic atrophy. Mitochondrion. 2019;46:262-269.